GlassScriptPhysician profile
Rao S Moravineni
NPI 1669584447
$151,073.84
in general payments reported to CMS, 2019-2025
56 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $13K · 2021: $29K · 2022: $24K · 2023: $29K · 2024: $18K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,042 · Travel and Lodging: $4,170 · Honoraria: $1,500 · Education: $345 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,472.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,375.10 |
| Food and Beverage | $7,042.01 |
| Travel and Lodging | $4,170.03 |
| Honoraria | $1,500.00 |
| Education | $345.05 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30,369.21 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $29,201.02 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $24,699.55 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Incyte Corporation | $13,668.08 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $8,418.91 | 2021-2025 | |
| Cti Biopharma Corp. | $5,239.05 | 2022-2023 | Vonjo |
| Emd Serono, INC. | $5,232.16 | 2024 | |
| Pfizer INC. | $5,198.64 | 2022-2025 | |
| Glaxosmithkline, LLC. | $5,012.60 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $3,852.36 | 2019-2025 | Talvey, Darzalex, Rybrevant |
| Avyxa Pharma, LLC | $3,369.55 | 2025 | |
| Pharmacosmos Therapeutics INC. | $2,661.04 | 2024 | Monoferric |
| Karyopharm Therapeutics INC. | $1,643.83 | 2021-2025 | Xpovio |
| Exelixis INC. | $1,554.48 | 2022-2025 | Cabometyx |
| Btg International INC. | $1,500.00 | 2024 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,381.99 | 2021-2023 | |
| Blueprint Medicines Corporation | $1,182.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $1,020.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $799.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $796.23 | 2024-2025 | Imfinzi, Lynparza, Tagrisso |
| Jazz Pharmaceuticals INC. | $515.00 | 2019 | |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Astellas Pharma US INC | $330.04 | 2023-2025 | Padcev, Vyloy |
| Abbvie INC. | $326.92 | 2024-2025 | |
| Celgene Corporation | $303.47 | 2020-2024 | Reblozyl, Pomalyst |
| Sobi, INC | $302.44 | 2023-2024 | |
| Gilead Sciences, INC. | $287.28 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $191.20 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Myriad Genetic Laboratories, INC. | $180.60 | 2023 | Myrisk |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Stemline Therapeutics INC. | $148.59 | 2023 | Orserdu, Elzonris |
| Takeda Pharmaceuticals U.S.A., INC. | $123.80 | 2019-2024 | Ninlaro, Fruzaqla |
| Seagen INC. | $112.28 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $95.94 | 2024-2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $75.53 | 2025 | Clonoseq |
| Genentech USA, INC. | $67.70 | 2024-2025 | Venclexta, Tecentriq |
| Mirati Therapeutics, INC. | $64.90 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $54.94 | 2024-2025 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $52.46 | 2025 | |
| Eisai INC. | $47.20 | 2024-2025 | |
| Beone Medicines USA, INC. | $46.91 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $42.80 | 2024-2025 | Qinlock, Romvimza |
| Tersera Therapeutics LLC | $40.65 | 2025 | Xermelo |
| Coherus Oncology, INC. | $40.48 | 2024 | |
| Legend Biotech USA INC. | $39.22 | 2025 | Carvykti |
| Janssen Scientific Affairs, LLC | $32.45 | 2025 | Rybrevant |
| Array Biopharma INC | $27.89 | 2024 | Lorbrena, Mektovi, Braftovi |
| Tempus Ai, INC | $27.32 | 2025 | Xt Cdx |
| Geron Corporation | $24.42 | 2025 | Rytelo |
| Foundation Medicine, INC. | $19.72 | 2023 | |
| Adc Therapeutics America, INC. | $17.98 | 2025 | |
| Amgen INC. | $17.77 | 2023 | Nplate, Vectibix, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.56 | 2025 | Erleada |
| Genmab U.S., INC. | $14.39 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rao Moravineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.